Charles de Water
Presidente en Econocom International BV .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Jean-Philippe Roesch | M | 62 |
Econocom International BV
Econocom International BV Electronics DistributorsDistribution Services Econocom International BV operates as a financial holding company with interests in computer equipment. The company was founded in 1985 and is headquartered in Nieuwegein, the Netherlands. | - |
Jan Smeitink | M | - |
Khondrion BV
Khondrion BV Pharmaceuticals: MajorHealth Technology Khondrion BV is a Dutch clinical-stage biopharmaceutical company that focuses on discovering and developing therapies for mitochondrial diseases. The company is based in Nijmegen, Netherlands, and was founded in 2012 by Jan Smeitink, who has been the CEO since then. The company's lead drug candidate, sonlicromanol, is a first-in-class, oral small molecule that targets key underlying mechanisms of primary mitochondrial disease. The compound has been granted orphan drug designations for the treatment of various mitochondrial diseases. Khondrion collaborates with a clinical and academic network and patient organizations internationally to accelerate the discovery and development of its potential medicines. | 12 años |
Walter Butler | M | 67 |
Econocom International BV
Econocom International BV Electronics DistributorsDistribution Services Econocom International BV operates as a financial holding company with interests in computer equipment. The company was founded in 1985 and is headquartered in Nieuwegein, the Netherlands. | - |
Jacques Adida | M | - |
Econocom International BV
Econocom International BV Electronics DistributorsDistribution Services Econocom International BV operates as a financial holding company with interests in computer equipment. The company was founded in 1985 and is headquartered in Nieuwegein, the Netherlands. | - |
Arnout Ploos van Amstel | M | 60 |
Khondrion BV
Khondrion BV Pharmaceuticals: MajorHealth Technology Khondrion BV is a Dutch clinical-stage biopharmaceutical company that focuses on discovering and developing therapies for mitochondrial diseases. The company is based in Nijmegen, Netherlands, and was founded in 2012 by Jan Smeitink, who has been the CEO since then. The company's lead drug candidate, sonlicromanol, is a first-in-class, oral small molecule that targets key underlying mechanisms of primary mitochondrial disease. The compound has been granted orphan drug designations for the treatment of various mitochondrial diseases. Khondrion collaborates with a clinical and academic network and patient organizations internationally to accelerate the discovery and development of its potential medicines. | 5 años |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
País | Relaciones | % del total |
---|---|---|
Países Bajos | 5 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Charles de Water
- Red Personal